News for Ambrx Biopharma Inc. (AMAM)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the e

In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2023...

Corbus Pharmaceuticals Holdings has seen an 800% stock price increase in 2024. See why CRBP is one of the best performing equities in the market right now.

Johnson & Johnson agreed to acquire Shockwave Medical Inc. for about $13.1 billion to bolster its expansion into making medical devices to treat heart disease.

Biotech ripe for ‘cascade of dealmaking’ - Here are the top companies to watch

According to a 2022 report published by Oracle, 45% of people have not felt true happiness for more than two years, while 25% have forgotten what it means to feel truly happy.

Johnson & Johnson acquires Ambrx Biopharma for $2 billion

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders...

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

In this article, we will be taking a look at the 20 fastest growing biotech companies in the US.

Here is how Ambrx Biopharma Inc. (AMAM) and HealthEquity (HQY) have performed compared to their sector so far this year.

A fresh look at Johnson & Johnson is warranted, especially in light of split-off of its Consumer Health segment and amid ongoing talc litigation. Learn more on JNJ stock here.

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.

In this article, we discuss billionaire Seth Klarman’s biotech stock picks.

Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.

Gainers LQR House Inc. (NASDAQ: LQR) shares surged 109% to $0.3602 in pre-market trading after the company delivered inaugural order to Costco, securing Von Payne Whiskey's presence on store shelves.

Sino Biopharm was approved to close its $161 million all-cash acquisition of F-star, a Cambridge, UK company that develops bispecific antibodies. Read more here...

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.